UTI Healthcare Fund Direct Growth

Fund Overview

Fund Size

₹1,126 Cr

Expense Ratio

1.30%

ISIN

INF789F01TO9

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

01 Jan 2013

About this fund

UTI Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by UTI Mutual Fund. This fund has been in existence for 12 years, 11 months and 11 days, having been launched on 01-Jan-13.
As of 11-Dec-25, it has a Net Asset Value (NAV) of ₹324.00, Assets Under Management (AUM) of 1126.13 Crores, and an expense ratio of 1.3%.

UTI Healthcare Fund Direct Growth has given a CAGR return of 15.96% since inception.
The fund's asset allocation comprises around 98.75% in equities, 0.00% in debts, and 1.25% in cash & cash equivalents.
You can start investing in UTI Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

-0.24%

— (Cat Avg.)

3 Years

+25.14%

+22.11% (Cat Avg.)

5 Years

+16.94%

+15.93% (Cat Avg.)

10 Years

+13.21%

+13.46% (Cat Avg.)

Since Inception

+15.96%

— (Cat Avg.)

Portfolio Summaryas of 30th November 2025

Equity	₹1,112.02 Cr	98.75%
Others	₹14.11 Cr	1.25%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹109.9 Cr	9.76%
Ajanta Pharma Ltd	Equity	₹72.98 Cr	6.48%
Lupin Ltd	Equity	₹66.54 Cr	5.91%
Glenmark Pharmaceuticals Ltd	Equity	₹45.74 Cr	4.06%
Dr Reddy's Laboratories Ltd	Equity	₹42.17 Cr	3.74%
Gland Pharma Ltd	Equity	₹38.92 Cr	3.46%
Apollo Hospitals Enterprise Ltd	Equity	₹38.88 Cr	3.45%
Alkem Laboratories Ltd	Equity	₹38.66 Cr	3.43%
Procter & Gamble Health Ltd	Equity	₹38.35 Cr	3.41%
Cipla Ltd	Equity	₹38.28 Cr	3.40%
Jupiter Life Line Hospitals Ltd	Equity	₹33.59 Cr	2.98%
Divi's Laboratories Ltd	Equity	₹32.39 Cr	2.88%
Aurobindo Pharma Ltd	Equity	₹30.67 Cr	2.72%
Eris Lifesciences Ltd Registered Shs	Equity	₹28.08 Cr	2.49%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹27.91 Cr	2.48%
Fortis Healthcare Ltd	Equity	₹25.73 Cr	2.29%
Caplin Point Laboratories Ltd	Equity	₹25 Cr	2.22%
Krishna Institute of Medical Sciences Ltd	Equity	₹24.19 Cr	2.15%
Ipca Laboratories Ltd	Equity	₹22.84 Cr	2.03%
Cohance Lifesciences Ltd	Equity	₹21.74 Cr	1.93%
Global Health Ltd	Equity	₹21.18 Cr	1.88%
Sai Life Sciences Ltd	Equity	₹20.31 Cr	1.80%
Aster DM Healthcare Ltd Ordinary Shares	Equity	₹20.3 Cr	1.80%
Sequent Scientific Ltd	Equity	₹19.47 Cr	1.73%
Pfizer Ltd	Equity	₹19.2 Cr	1.71%
Anthem Biosciences Ltd	Equity	₹19.16 Cr	1.70%
Metropolis Healthcare Ltd	Equity	₹18.68 Cr	1.66%
Sudeep Pharma Ltd	Equity	₹15.86 Cr	1.41%
Marksans Pharma Ltd	Equity	₹14.19 Cr	1.26%
Net Current Assets	Cash	₹14 Cr	1.24%
Windlas Biotech Ltd	Equity	₹12.28 Cr	1.09%
Vijaya Diagnostic Centre Ltd	Equity	₹11.98 Cr	1.06%
Biocon Ltd	Equity	₹11.95 Cr	1.06%
Syngene International Ltd	Equity	₹11.67 Cr	1.04%
Acutaas Chemicals Ltd	Equity	₹11.62 Cr	1.03%
Sanofi Consumer Healthcare India Ltd	Equity	₹11.26 Cr	1.00%
Torrent Pharmaceuticals Ltd	Equity	₹10.8 Cr	0.96%
Rainbow Childrens Medicare Ltd	Equity	₹10.63 Cr	0.94%
Emcure Pharmaceuticals Ltd	Equity	₹10.61 Cr	0.94%
Alembic Pharmaceuticals Ltd	Equity	₹9.92 Cr	0.88%
Jubilant Pharmova Ltd	Equity	₹9.77 Cr	0.87%
Orchid Pharma Ltd	Equity	₹8.33 Cr	0.74%
Dr. Lal PathLabs Ltd	Equity	₹6.1 Cr	0.54%
Laxmi Dental Ltd	Equity	₹4.2 Cr	0.37%
Clearing Corporation Of India Ltd. Std - Margin	Cash - Repurchase Agreement	₹0.11 Cr	0.01%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹1,100.4 Cr	97.71%
Basic Materials	₹11.62 Cr	1.03%

Risk & Performance Ratios

Fund Managers

Kamal Gada

Since May 2022

Additional Scheme Detailsas of 30th November 2025

ISIN

INF789F01TO9

Expense Ratio

1.30%

Exit Load

1.00%

Fund Size

₹1,126 Cr

Age

12 years 11 months

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Bandhan Healthcare Fund Direct Growth Very High Risk	-	0.0%	-	-
Bandhan Healthcare Fund Regular Growth Very High Risk	-	0.0%	-	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.4%	1.0%	₹611.32 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.3%	1.0%	₹611.32 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹338.55 Cr	-
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹338.55 Cr	-
PGIM India Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹106.92 Cr	1.2%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹106.92 Cr	-0.5%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹501.89 Cr	3.5%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹501.89 Cr	5.3%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹11.12 Cr	2.5%
Kotak Healthcare Fund Direct Growth Very High Risk	0.8%	0.0%	₹481.99 Cr	-2.2%
Kotak Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹481.99 Cr	-3.8%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹2010.77 Cr	4.5%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹2010.77 Cr	5.8%
Nippon India Pharma Fund Direct Growth Very High Risk	0.9%	1.0%	₹8458.68 Cr	0.6%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.9%	1.0%	₹6459.82 Cr	3.2%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.0%	1.0%	₹6459.82 Cr	4.1%
DSP Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹3178.53 Cr	-4.1%
DSP Healthcare Fund Regular Growth Very High Risk	1.9%	0.0%	₹3178.53 Cr	-5.4%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.2%	1.0%	₹86.00 Cr	-2.8%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.5%	1.0%	₹86.00 Cr	-4.0%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹383.96 Cr	-5.2%
quant Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹383.96 Cr	-6.8%
UTI Healthcare Fund Direct Growth Very High Risk	1.3%	1.0%	₹1126.13 Cr	-0.2%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹4130.76 Cr	-1.0%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹1338.85 Cr	-1.0%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹1338.85 Cr	0.5%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹129.47 Cr	2.6%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹4130.76 Cr	-2.0%
Nippon India Pharma Fund Regular Growth Very High Risk	1.8%	1.0%	₹8458.68 Cr	-0.3%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1126.13 Cr	-1.2%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹20.69 Cr	2.4%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1033.98 Cr	2.7%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2821.22 Cr	-0.2%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2821.22 Cr	1.3%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹232.83 Cr	-8.1%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹232.83 Cr	-6.4%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹46.77 Cr	2.5%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹853.63 Cr	-1.2%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹853.63 Cr	0.1%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹38.10 Cr	-0.6%

About the AMC

UTI Mutual Fund

+91-22-6678 6666

https://www.utimf.com/

Total AUM

₹3,61,558 Cr

Address

UTI Towers, Gn Block, Mumbai, 400 051

Other Funds by UTI Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
UTI Children's Equity Fund Direct Growth Very High Risk	1.2%	0.0%	₹1179.90 Cr	0.0%
UTI Multi Cap Fund Direct Growth Very High Risk	0.3%	1.0%	₹1576.18 Cr	-
UTI Income Plus Arbitrage Active Fund of Fund Direct Growth Moderately High risk	0.1%	0.0%	₹264.86 Cr	-
UTI Nifty India Manufacturing Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹25.16 Cr	-
UTI Nifty Midsmallcap 400 Momentum Quality 100 Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹95.04 Cr	-
UTI Quant Fund Direct Growth Very High Risk	0.3%	1.0%	₹1863.27 Cr	-
UTI Nifty Alpha Low-Volatility 30 Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹81.24 Cr	-4.1%
UTI Nifty Midcap 150 Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹62.04 Cr	0.1%
UTI Nifty Private Bank Index Fund Direct Growth Very High Risk	0.7%	0.0%	₹228.32 Cr	10.9%
UTI Nifty200 Quality 30 Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹658.51 Cr	-1.3%
UTI Innovation Fund Direct Growth Very High Risk	0.9%	1.0%	₹843.47 Cr	-9.9%
UTI Fixed Income Interval Fund Annual Plan I Direct Growth Low Risk	-	0.0%	₹13.13 Cr	6.0%
UTI Fixed Term Income Fund - Series XXXV-I (1260 Days) Direct Growth Low Risk	-	0.0%	₹316.65 Cr	7.1%
UTI Fixed Term Income Fund - Series XXXV-III (1176 Days) Direct Growth Low to Moderate Risk	-	0.0%	₹42.79 Cr	6.9%
UTI FIIF Ser 2 Qt Interval V Direct Growth Low Risk	-	1.0%	₹2.20 Cr	6.3%
UTI Fixed Income Interval Fund Quarterly I Direct Growth Low Risk	-	0.0%	₹9.74 Cr	6.5%
UTI Fixed Inc Intvl Series2 Qt Intvl VI Direct Growth Moderate Risk	-	1.0%	₹8.54 Cr	6.8%
UTI-Fixed Term Income Fund - Series XXX-VI (1107 days) Direct Growth Low to Moderate Risk	-	0.0%	-	10.0%
UTI-Fixed Term Income Fund - Series XXX - VII (1294 days) Direct Growth Low to Moderate Risk	-	0.0%	-	-
UTI Fixed Term Income Fund - Series XXXV-II (1223 Days) Direct Growth Low Risk	-	-	₹176.51 Cr	7.1%
UTI Fixed Income Interval Fund Annual Plan III Direct Growth Low to Moderate Risk	-	0.0%	₹13.38 Cr	6.9%
UTI Fixed Term Income Fund - Series XXXVI-I (1574 days) Direct Growth Low to Moderate Risk	-	0.0%	₹57.60 Cr	8.2%
UTI Floater Fund Direct Growth Low to Moderate Risk	0.4%	0.0%	₹1461.56 Cr	7.5%
UTI Nifty 500 Value 50 Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹539.39 Cr	1.2%
UTI Banking & PSU Debt Fund Direct Growth Low to Moderate Risk	0.3%	0.0%	₹811.55 Cr	8.0%
UTI Focused Equity Fund Direct Growth Very High Risk	0.6%	1.0%	₹2638.30 Cr	2.0%
UTI Silver ETF Fund of Fund Direct Growth Very High Risk	0.1%	1.0%	₹294.52 Cr	96.4%
UTI Nifty200 Momentum 30 Index Fund Direct Growth Very High Risk	0.5%	0.0%	₹8942.61 Cr	-11.3%
UTI Overnight Fund Direct Growth Low Risk	0.1%	0.0%	₹5369.32 Cr	5.9%
UTI Corporate Bond Fund Direct Growth Moderate Risk	0.3%	0.0%	₹5746.75 Cr	8.0%
UTI Nifty Midcap 150 Quality 50 Index Fund Direct Growth Very High Risk	0.6%	0.0%	₹259.07 Cr	-5.4%
UTI Arbitrage Fund Direct Growth Low Risk	0.3%	0.0%	₹10719.99 Cr	7.1%
UTI Small Cap Fund Direct Growth Very High Risk	0.6%	1.0%	₹4833.23 Cr	-7.7%
UTI Ultra Short Term Fund Direct Growth Moderate Risk	0.3%	0.0%	₹4787.82 Cr	7.3%
UTI Credit Risk Fund Direct Growth Moderately High risk	0.9%	1.0%	₹261.16 Cr	8.0%
UTI Dividend Yield Fund Direct Growth Very High Risk	1.5%	1.0%	₹3936.48 Cr	0.7%
UTI Banking and Financial Services Fund Direct Growth Very High Risk	1.1%	1.0%	₹1385.87 Cr	10.9%
UTI Dynamic Bond Fund Direct Growth Moderate Risk	0.7%	0.0%	₹456.79 Cr	6.8%
UTI Hybrid Equity Fund Direct Growth Very High Risk	1.2%	1.0%	₹6717.89 Cr	2.9%
UTI Long Term Equity Fund Direct Growth Very High Risk	0.9%	0.0%	₹3784.72 Cr	0.6%
UTI Flexi Cap Fund Direct Growth Very High Risk	1.0%	1.0%	₹25575.00 Cr	-1.5%
UTI Bond Fund Direct Growth Moderate Risk	1.2%	0.0%	₹312.61 Cr	5.8%
UTI Liquid Fund Cash Plan Direct Growth Low to Moderate Risk	0.1%	0.0%	₹24570.02 Cr	6.7%
UTI Gilt Fund Direct Growth Moderate Risk	0.7%	0.0%	₹560.78 Cr	5.1%
UTI India Consumer Fund Direct Growth Very High Risk	1.6%	1.0%	₹738.06 Cr	1.0%
UTI Infrastructure Fund Direct Growth Very High Risk	1.9%	1.0%	₹2200.11 Cr	-2.1%
UTI MNC Fund Direct Growth Very High Risk	1.3%	1.0%	₹2872.30 Cr	-0.4%
UTI Master Share Unit Scheme Direct Growth Very High Risk	0.9%	1.0%	₹13398.93 Cr	4.8%
UTI Regular Savings Fund Direct Growth Moderately High risk	1.2%	1.0%	₹1701.31 Cr	5.1%
UTI Money Market Fund Direct Growth Low to Moderate Risk	0.1%	0.0%	₹22197.93 Cr	7.6%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of UTI Healthcare Fund Direct Growth?

The NAV of UTI Healthcare Fund Direct Growth, as of 11-Dec-2025, is ₹324.00.

What are the returns of UTI Healthcare Fund Direct Growth?

The fund has generated -0.24% over the last 1 year and 25.14% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of UTI Healthcare Fund Direct Growth?

The fund's allocation of assets is distributed as 98.75% in equities, 0.00% in bonds, and 1.25% in cash and cash equivalents.

Who manages the UTI Healthcare Fund Direct Growth?

The fund managers responsible for UTI Healthcare Fund Direct Growth are:-

Kamal Gada

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

Fund Overview

Fund Size

₹1,126 Cr

Expense Ratio

1.30%

ISIN

INF789F01TO9

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

01 Jan 2013

Risk Level

Your principal amount will be at Very High Risk